Skip to main content
Veterinary Medicines

L-Polamivet vet injektioneste, liuos

Authorised
  • Levomethadone hydrochloride
  • Fenpipramide hydrochloride

Product identification

Medicine name:
L-Polamivet vet injektioneste, liuos
Active substance:
  • Levomethadone hydrochloride
  • Fenpipramide hydrochloride
Target species:
  • Dog
  • Horse
Route of administration:
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Levomethadone hydrochloride
    2.50
    milligram(s)
    /
    1.00
    millilitre(s)
  • Fenpipramide hydrochloride
    0.13
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Dog
      • Not applicable
        no withdrawal period
  • Intravenous use
    • Horse
      • Not specified
        0
        day
    • Dog
      • Not applicable
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN02AC52
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International GmbH
Responsible authority:
  • FIMEA
Authorisation number:
  • 6022
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 28/01/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 28/01/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."